Gregg Gilbert
Stock Analyst at Truist Securities
(2.33)
# 2,343
Out of 4,829 analysts
91
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $11.20 | +51.79% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $29.56 | +25.17% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $48.18 | +74.35% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $755.57 | -30.52% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $9.98 | +30.26% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $18.57 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $80.43 | +15.63% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $14.39 | +233.56% | 2 | Feb 2, 2021 | |
| CHRS Coherus BioSciences | Initiates: Buy | $26 | $1.02 | +2,449.02% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.63 | +23,664.26% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $26.99 | +189.00% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $161.92 | -51.83% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $17.96 | +0.22% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $106.38 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $103.58 | +68.95% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $190.07 | -65.28% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $11.20
Upside: +51.79%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $29.56
Upside: +25.17%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $48.18
Upside: +74.35%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $755.57
Upside: -30.52%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $9.98
Upside: +30.26%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $18.57
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $80.43
Upside: +15.63%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $14.39
Upside: +233.56%
Coherus BioSciences
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.02
Upside: +2,449.02%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.63
Upside: +23,664.26%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $26.99
Upside: +189.00%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $161.92
Upside: -51.83%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $17.96
Upside: +0.22%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $106.38
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $103.58
Upside: +68.95%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $190.07
Upside: -65.28%